Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.

Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G.

Cancer Biother Radiopharm. 2006 Apr;21(2):106-16.

PMID:
16706631
2.

Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.

Yoon SO, Lee TS, Kim SJ, Jang MH, Kang YJ, Park JH, Kim KS, Lee HS, Ryu CJ, Gonzales NR, Kashmiri SV, Lim SM, Choi CW, Hong HJ.

J Biol Chem. 2006 Mar 17;281(11):6985-92. Epub 2006 Jan 9.

3.

SDR grafting--a new approach to antibody humanization.

Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J.

Methods. 2005 May;36(1):25-34. Review.

PMID:
15848072
4.

Minimizing the immunogenicity of antibodies for clinical application.

Gonzales NR, De Pascalis R, Schlom J, Kashmiri SV.

Tumour Biol. 2005 Jan-Feb;26(1):31-43. Review.

PMID:
15741769
5.

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H.

Blood. 2005 Apr 1;105(7):2862-8. Epub 2004 Dec 9.

PMID:
15591121
6.

SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV.

Mol Immunol. 2004 Jul;41(9):863-72.

PMID:
15261458
7.

Developing a minimally immunogenic humanized antibody by SDR grafting.

Kashmiri SV, De Pascalis R, Gonzales NR.

Methods Mol Biol. 2004;248:361-76. No abstract available.

PMID:
14970508
8.
9.

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV.

Mol Immunol. 2003 Oct;40(6):337-49.

PMID:
14522015
10.

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.

De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV.

J Immunol. 2002 Sep 15;169(6):3076-84.

11.

Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies.

Gonzales NR, Schuck P, Schlom J, Kashmiri SV.

J Immunol Methods. 2002 Oct 15;268(2):197-210.

PMID:
12215388
12.

Multivalent single-chain antibodies for radioimaging of tumors.

Kashmiri SV.

J Nucl Med. 2001 Oct;42(10):1528-9. No abstract available.

13.

Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens.

Park SS, Ryu CJ, Kang YJ, Kashmiri SV, Hong HJ.

Mol Immunol. 2000 Dec;37(18):1123-30.

PMID:
11451417
14.

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.

Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.

Cancer Res. 2001 Mar 15;61(6):2523-32.

15.

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J.

Crit Rev Oncol Hematol. 2001 Apr;38(1):3-16. Review.

PMID:
11255077
16.

A CDR-grafted (humanized) domain-deleted antitumor antibody.

Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH.

Cancer Biother Radiopharm. 1997 Oct;12(5):305-16.

PMID:
10851481
17.

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.

Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SV.

Mol Immunol. 1999 Oct-Nov;36(15-16):1079-91.

PMID:
10698310
19.

Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.

Santos AD, Kashmiri SV, Hand PH, Schlom J, Padlan EA.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3118s-3123s.

PMID:
10541352
20.

Targeting strategies for cancer radiotherapy.

Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s.

PMID:
10541342
21.

Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions.

Lee HS, Shu L, De Pascalis R, Giuliano M, Zhu M, Padlan EA, Hand PH, Schlom J, Hong HJ, Kashmiri SV.

Mol Immunol. 1999 Jan;36(1):61-71.

PMID:
10369421
22.

Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.

McGuinness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG.

Hum Gene Ther. 1999 Jan 20;10(2):165-73.

PMID:
10022542
23.

The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice.

Bei R, Guptill V, Masuelli L, Kashmiri SV, Muraro R, Frati L, Schlom J, Kantor J.

J Immunother. 1998 May;21(3):159-69.

PMID:
9610907
24.

In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response.

Prasad GL, Lee HS, Iwahashi M, Milenic DE, Abrams S, Schlom J, Kashmiri SV.

Cancer Gene Ther. 1997 Jul-Aug;4(4):253-9.

PMID:
9253511
25.

Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein.

Shu L, Qi CF, Hand PH, Schlom J, Kashmiri SV.

Immunotechnology. 1995 Dec;1(3-4):231-41.

PMID:
9373351
26.

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.

Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, et al.

Cancer Res. 1995 Dec 1;55(23 Suppl):5957s-5967s.

27.

Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein.

Bei R, Schlom J, Kashmiri SV.

J Immunol Methods. 1995 Oct 26;186(2):245-55.

PMID:
7594624
28.

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH.

Hybridoma. 1995 Oct;14(5):461-73.

PMID:
8575795
29.

Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery.

Nicolet CM, Burkholder JK, Gan J, Culp J, Kashmiri SV, Schlom J, Yang NS, Sondel PM.

Cancer Gene Ther. 1995 Sep;2(3):161-70.

PMID:
8528959
30.

Generation, purification, and characterization of a recombinant source of human prostate-specific antigen.

Bei R, Paranavitana C, Milenic D, Kashmiri SV, Schlom J.

J Clin Lab Anal. 1995;9(4):261-8.

PMID:
7562244
31.

Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA.

Bei R, Kantor J, Kashmiri SV, Abrams S, Schlom J.

J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):275-82.

PMID:
7881636
32.

Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.

Yamaue H, Kashmiri SV, De Filippi R, Nieroda C, Yannelli JR, Tsang KY, Schlom J.

J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):262-74.

PMID:
7881635
33.

The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli.

Sawyer JR, Schlom J, Kashmiri SV.

Protein Eng. 1994 Nov;7(11):1401-6.

PMID:
7700873
34.

Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen.

Bei R, Kantor J, Kashmiri SV, Schlom J.

Mol Immunol. 1994 Jul;31(10):771-80.

PMID:
7518569
35.

Monoclonal antibody gene transfer. Implications for tumor-specific cell-mediated cytotoxicity.

Primus FJ, Finch MD, Wetzel SA, Masci AM, Schlom J, Kashmiri SV.

Ann N Y Acad Sci. 1994 May 31;716:154-65; discussion 165-6. No abstract available.

PMID:
8024192
36.

Potential for recombinant immunoglobulin constructs in the management of carcinoma.

Hand PH, Kashmiri SV, Schlom J.

Cancer. 1994 Feb 1;73(3 Suppl):1105-13. Review.

PMID:
8306254
37.

Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'.

Abergel C, Padlan EA, Kashmiri SV, Milenic D, Calvo B, Schlom J.

Proteins. 1993 Dec;17(4):438-43.

PMID:
8108385
38.

Secretion of a single-gene-encoded immunoglobulin from myeloma cells.

Shu L, Qi CF, Schlom J, Kashmiri SV.

Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7995-9.

39.

Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes.

Primus FJ, Finch MD, Masci AM, Schlom J, Kashmiri SV.

Cancer Res. 1993 Jul 15;53(14):3355-61.

40.

Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.

Tsang KY, Kashmiri SV, Qi CF, Nieroda C, Calvo B, De Filippi R, Greiner JW, Primus FJ, Schlom J.

Immunol Lett. 1993 May;36(2):179-85.

PMID:
8102353
41.

A human T cell line engineered to secrete chimeric monoclonal antibody.

Tsang KY, Kashmiri SV, De Filippi R, Qi CF, Calvo B, Shu L, Nieroda CA, Greiner JW, Schlom J.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):143-52.

PMID:
8471589
42.

Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.

Slavin-Chiorini DC, Horan Hand PH, Kashmiri SV, Calvo B, Zaremba S, Schlom J.

Int J Cancer. 1993 Jan 2;53(1):97-103.

PMID:
8416208
43.

Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody.

Calvo B, Kashmiri SV, Hutzell P, Hand PH, Slavin-Chiorini DC, Schlom J, Zaremba S.

Cancer Biother. 1993 Spring;8(1):95-109.

PMID:
7529083
44.

Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.

Hand PH, Calvo B, Milenic D, Yokota T, Finch M, Snoy P, Garmestani K, Gansow O, Schlom J, Kashmiri SV.

Cancer Immunol Immunother. 1992;35(3):165-74.

PMID:
1638552
45.

Correlation of DNA hypomethylation with expression of carcinoembryonic antigen in human colon carcinoma cells.

Tran R, Kashmiri SV, Kantor J, Greiner JW, Pestka S, Shively JE, Schlom J.

Cancer Res. 1988 Oct 15;48(20):5674-9.

46.

No involvement of bovine leukemia virus in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Bender AP, Robison LL, Kashmiri SV, McClain KL, Woods WG, Smithson WA, Heyn R, Finlay J, Schuman LM, Renier C, et al.

Cancer Res. 1988 May 15;48(10):2919-22.

47.

Enhanced expression of the c-myc gene in bovine leukemia virus-induced bovine tumors.

Gupta P, Kashmiri SV, Erisman MD, Rothberg PG, Astrin SM, Ferrer JF.

Cancer Res. 1986 Dec;46(12 Pt 1):6295-8.

48.
49.

Methylation and expression of bovine leukemia proviral DNA.

Kashmiri SV, Mehdi R, Gupta P, Ferrer JF.

Biochem Biophys Res Commun. 1985 May 31;129(1):126-33.

PMID:
2988545

Supplemental Content

Loading ...
Support Center